Akili Interactive Labs, Inc.
17
0
3
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
54%
7 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
EndeavorOTC™ Prospective Product Registry
Role: lead
EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")
Role: lead
EndeavorOTC® Research Study in College Students
Role: lead
Improving Cognitive Health in COVID-19 Survivors
Role: collaborator
Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01
Role: lead
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
Role: lead
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
Role: lead
Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult)
Role: lead
Study of Attention and Memory Treatments for Cancer Survivors
Role: collaborator
Digital Cognition in Multiple Sclerosis
Role: collaborator
Software Treatment for Actively Reducing Severity of ADHD
Role: lead
Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
Role: collaborator
Software Treatment for Actively Reducing Severity of ADHD - Follow Up
Role: lead
Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)
Role: lead
Cognitive ADHD Videogame Exploratory Study
Role: lead
Feasibility & Characterization of Project: EVO Monitor Cognitive Measurements
Role: lead
Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents
Role: lead
All 17 trials loaded